Loading…
PCSA
Processa Pharmaceuticals, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 74275C403
$1.84+1.10%Price as of Sep 28, 20:02 UTC · updated once a day, after the close
Key metrics
- Market cap
- $5.14M
- P/E
- 2.8x
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- $0.65
- ROE
- -464.20%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.97
- 52-week high
- $14.25
- 52-week low
- $1.67
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.9% over 5Y.
today you would have $0.43▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.88 | $22.10 | $167.50 | $550.00 | $2,450.00 | $3,297.50 | $9,000.00 | $12,600.00 | $15,400.00 | $6,125.00 | $9,800.00 | $53,900.00 | |
| P/S | 224.7x | — | — | — | — | — | — | — |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$14.58
Median P/E of 22.4 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AMIXAutonomix Medical, Inc. | $5.32 | — | 0.9x | — | -315.99% | $5.17M |
| BRTXBioRestorative Therapies, Inc. | $0.20 | — | 1.7x | — | -241.14% | $5.07M |
| POASPHAOS TECHNOLOGY HOLDINGS (CAYMAN) Ltd | $0.17 | — | — | — | — | $5.21M |
| ERNAErnexa Therapeutics Inc. | $4.57 |
About the company
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
- 12
- Vero Beach, United States
Company description provided by Yahoo Finance.